					Sheet 2 of 3			
PTO-		REPRO		ATTORNEY DOCKET NO. 2316.1002-001	APPLICATION NO. T NO. 09/965,135 MAR			
		INFOR	MATION DISCLOSURE CITATION IN AN APPLICATION MAR 1 9 2002	APPLICANT Walter H. Günzburg, et	1E 2			
		-	March 13, 2002	FILING DATE September 27, 2001	GROUP 600,2002 1648 /2900 Pages, Etc.)			
_	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Mohan, N., et al., "Production and Characterization of an Mls-1-specific							
S		AU	Monoclonal Antibody, " J. Exp. Med, 177:351-358 (1993)					
		AV	Krummenacher, C., et al., "The Mouse Mammary Tumor Virus Long Terminal Repeat Encodes a 47 kDa Glycoprotein with a Short Half-Life in Mammalian Cells,"  Molecular Immunology, 30(13):1151-1157 (1993)					
		AW	Günzburg, W.H., et al., "Endogenous superantigen expression controlled by a novel promoter in the MMTV long terminal repeat," Nature, 364:154-158 (1993)					
		AX	Winslow, G.M., et al., "Detection and Biochemical Characterization of the Mouse Mammary Tumor Virus 7 Superantigen (Mls-1 <sup>a</sup> )," Cell, 71:719-730 (1992)					
		AY	Knight, A.M., et al., "Biochemical analysis of the mouse mammary tumor virus long terminal repeat product. Evidence for the molecular structure of an endogenous superantigen," Eur. J. Immunol., 22:879-882 (1992)					
		AZ	Korman, A.J., et al., "The mouse mammary tumour virus long terminal repeat encodes a type II transmembrane glycoprotein," The EMBO Journal, 11(5):1901-1905 (1992)					
		AR2	Huber, B.T., "Mls genes and self-superantigens," TIG, 8(11):399-402 (1992)					
	$\left[ \right]$	AS2	Pullen, A.M., et al., "The Open Reading Frames in the 3' Long Terminal Repeats of Several Mouse Mammary Tumor Virus Integrants Encode V $\beta$ 3-specific Superantigens," J. Exp. Med., 175:41-47 (1992)					
		AT2	Günzburg, W.H., et al., "Factors controlling the expression of mouse mammary tumour virus," Biochem. J., 283:625-632 (1992)					
		AU2	Acha-Orbea, H., et al., "Clonal deletion of Vβ14-bearing T cells in mice transgenic for mammary tumour virus," <i>Nature</i> , 350:207-211 (1991)					
		AV2	Choi, Yongwon, et al., "A superantigen encoded in the open reading frame of the 3' long terminal repeat of mouse mammary tumour virus," Nature, 350:203-207 (1991)					
		AW2	Brandt-Carlson, C., et al., "Detection and Characterization of a Glycoprotein Encoded by the Mouse Mammary Tumor Virus Long Terminal Repeat Gene," Journal of Virology, 65(11):6051-6060 (1991)					
		AX2	Salmons, B., et al., "Current perspectives in the biology of mouse mammary tumour virus," Virus Research, 8:81-102 (1987)					
		AY2	Salmons, B., et al., "naf, a trans-Regulating Negative-Acting Factor Encoded within the Mouse Mammary Tumor Virus Open Reading Frame Region," Journal of Virology, 64(12):6355-6359 (1990)					
A)	Hornsby, P.J., et al., "A Modified Procedure for Replica Plating of Mammalian Cells Allowing Selection of Clones Based on Gene Expression," BioTechniques, 12(2):244-249 (1992)							
EXAMINER DATE CONSIDERED 10/17/3								

			Sheet 3 of	<u> </u>				
PTO-1449 REPRO	DDUCED .	ATTORNEY DOCKET NO. 2316.1002-001	APPLICATION NO. 09/965,135	MAR H CEN				
INFORI	MATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT Walter H. Günzburg, et	. al.	2 1 2002 TER 1600/2900				
100	March 13, 2002	FILING DATE	GROUP	2002 1600/				
I P E WA	several sheets if necessary)	September 27, 2001	1648	)2 0/23				
9 20 M &	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
SF ARA	Wintersperger, S., et al., "Negative-acting factor and superantigen are separable activities of the mouse mammary tumor virus long terminal repeat,"  Proc. Natl. Acad. Sci. USA, 92:2745-2749 (1995)							
AS3	AS3 Salmons, B., et al., "Production of Mouse Mammary Tumor Virus upon Transfection of a Recombinant Proviral DNA into Cultured Cells," Virology, 144:101-114 (1985)							
АТЗ	Donehower, L.A., et al., "Regulatory and Coding Potential of the Mouse Mammary Tumor Virus Long Terminal Redundancy," Journal of Virology, 37(1):226-238 (1981)							
AU3	AU3 Günzburg, W.H., et al., "Retroviral Vectors Directed to Predefined Cell Types for Gene Therapy," Biologicals, 23:5-12 (1995)							
AV3	Wintersperger, S., et al., "Superantigen and NAF Activities Of Mouse Mammary Tumour Virus Can Be Separated," J. Cell. Biochem., Supplemental 17D:54 (13 March 1993)							
EWA	Jane, S.M., et al., "Vector Development: A Major Obstacle In Human Gene Therapy," Ann. Med., 30(5):413-415 (1998)							
AX3	Kaplitt, M.G., et al., "Genetic Modification of Cells with Retrovirus Vectors." In Viral Vectors, M.G.Kaplitt et al., eds. (San Diego, CA: Academic Press, Inc.), pp. 215-216 and 229 (1995)							
AY3	Salmons, B., et al., "naf, a trans-Regulating Negative-Acting Factor Encoded within the Mouse Mammary Tumor Virus Open Reading Frame Region," J. Virol. 64(12):6355-6359 (1990)							
AZ3	Dorland's Illustrated Med p. 1373 (1994)	ical Dictionary, 28 <sup>th</sup> Ec	d., W.B. Saunders	s Co.,				
AR4	Fasel, N., et al., "The Region of Mouse Mammary Tumor Virus DNA Containing the Long Terminal Repeat Includes a Long Coding Sequence and Signals for Hormonally Regulated Transcription," EMBO Journal 1(1):3-7 (1982)							
AS4	Wintersperger, S., et al., "A Transient Assay for Gene Expression Studies in B Lymphocytes and Its Use for Superantigen Assays,"  BioTechniques 16(5):882-886 (1994)							
Fasel, N., et al., GR Mouse Mammary Tumor Virus Long Terminal Possibly Encoding a Protein. Accession No. V01175 X16475.								
EXAMINER	han Tole	DATE CONSIDERED / / / / / / / / / / / / / / / / / / /						